Related Experiment Video
Updated: Aug 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipid risk factors and the regression of atherosclerosis
1Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.
Related Concept Videos
Inflammation
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease I: Introduction
Atherosclerosis I: Introduction
Atherosclerosis III: Management

